PFIZER INC.

Pfizer's investigational P-selectin inhibitor inclacumab failed to meet its primary endpoint of reducing vaso-occlusive crises in a Phase III trial for sickle cell disease.

The U.S. District Court for the District of Delaware entered a final judgment on July 30, 2025, ruling that Pfizer's COVID-19 vaccine did not infringe any of Alnylam's patents covering nanoparticle technology.

Schrödinger has terminated development of its CDC7 inhibitor SGR-2921 after two patient deaths in a Phase I trial for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.

The Department of Health and Human Services issued a stop work order on August 5, 2025, halting Vaxart's Phase IIb trial for VXA-CoV2-3.3, an oral COVID-19 vaccine that had enrolled approximately 5,000 of its targeted 10,000 participants.

The FDA is considering not renewing Pfizer's emergency use authorization for its COVID-19 vaccine in children aged 6 months to 4 years for the upcoming respiratory season.

GSK will receive $370 million upfront from CureVac following a patent settlement involving BioNTech and Pfizer over mRNA vaccine technology, with $320 million paid in cash.

Chai Discovery secured $70 million in Series A funding led by Menlo Ventures, bringing total funding to $100 million to advance AI-driven drug discovery.

Novo Nordisk announced plans to initiate Phase 3 trials for coramitug, a potential first-in-class amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy, following successful completion of a Phase 2 study.

Nxera Pharma has launched a broad proprietary pipeline targeting obesity and chronic weight management, led by a new oral small molecule GLP-1 agonist program.